Applications and perspectives of metastatic colorectal cancer organoids
Currently, colorectal cancer (CRC) is one of the most malignancies in the world, with high rates of morbidity and mortality. More than 50% of patients will eventually develop tumor metastasis, and patients with metastatic colorectal cancer (mCRC) are not sensitive to most drugs, leading to a poorer...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of New Medicine
2024-06-01
|
| Series: | Yixue xinzhi zazhi |
| Subjects: | |
| Online Access: | https://yxxz.whuznhmedj.com/futureApi/storage/attach/2406/uvFxGH32sfMyocMwWwKreuc15LIrbpztfRwVyEnr.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Currently, colorectal cancer (CRC) is one of the most malignancies in the world, with high rates of morbidity and mortality. More than 50% of patients will eventually develop tumor metastasis, and patients with metastatic colorectal cancer (mCRC) are not sensitive to most drugs, leading to a poorer prognosis for patients. Although studies of mCRC using patient-derived cancer cells and patient-derived xenografts (PDX) are mature, both still have limitations. However, patient-derived organoids (PDO) has the benefits of duplicating the immune circumstance of real tumor in vivo, preserving tumor heterogeneity, short culture cycles and easy preservation. And it has shown great application value in the fundamental study of mCRC, explanation of the mechanism of drug action, development of new drugs and individualized treatment. In order to explain the importance of organoids in mCRC research and offer directions for future research, this paper summarizes the recent studies and difficulties of organoid technology in recent years. |
|---|---|
| ISSN: | 1004-5511 |